BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7438460)

  • 21. Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas.
    Herle AJ; Uller RP
    J Clin Invest; 1975 Aug; 56(2):272-7. PubMed ID: 1150869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The correlation between serum thyroglobulin and iodine-131 scanning in detecting metastases in patients with a differentiated thyroid carcinoma].
    Abduluakhab M; Gavrilov M; Mladenov B
    Khirurgiia (Sofiia); 1997; 50(4):33-6. PubMed ID: 9739856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thallium-201 uptake with negative iodine-131 scintigraphy and serum thyroglobulin in metastatic oxyphilic papillary thyroid carcinoma.
    Harder W; Lind P; Molnar M; Mikosch P; Gomez I; Gallowitsch HJ; Kresnik E; Unterweger O; Dinges HP
    J Nucl Med; 1998 Feb; 39(2):236-8. PubMed ID: 9476925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.
    Schlüter B; Bohuslavizki KH; Beyer W; Plotkin M; Buchert R; Clausen M
    J Nucl Med; 2001 Jan; 42(1):71-6. PubMed ID: 11197983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thallium-201 scintigraphy in differentiated thyroid cancer: comparison with radioiodine scintigraphy and serum thyroglobulin determinations.
    Ramanna L; Waxman A; Braunstein G
    J Nucl Med; 1991 Mar; 32(3):441-6. PubMed ID: 2005453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tc-99m MIBI SPECT in detecting metastatic papillary thyroid carcinoma in patients with elevated human serum thyroglobulin levels but negative I-131 whole body scan.
    Hsu CH; Liu FY; Yen RF; Kao CH
    Endocr Res; 2003 Feb; 29(1):9-15. PubMed ID: 12665314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study.
    Koh JM; Kim ES; Ryu JS; Hong SJ; Kim WB; Shong YK
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):421-7. PubMed ID: 12641624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.
    Oyen WJ; Verhagen C; Saris E; van den Broek WJ; Pieters GF; Corsten FH
    J Nucl Med; 2000 Apr; 41(4):643-6. PubMed ID: 10768565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases.
    Filesi M; Signore A; Ventroni G; Melacrinis FF; Ronga G
    J Nucl Med; 1998 Sep; 39(9):1542-6. PubMed ID: 9744339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma.
    Ringel MD; Balducci-Silano PL; Anderson JS; Spencer CA; Silverman J; Sparling YH; Francis GL; Burman KD; Wartofsky L; Ladenson PW; Levine MA; Tuttle RM
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4037-42. PubMed ID: 10566646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum thyroglobulin levels predict total body iodine scan findings in patients with treated well-differentiated thyroid carcinoma.
    Charles MA; Dodson LE; Waldeck N; Hofeldt F; Ghaed N; Telepak R; Ownbey J; Burstein P
    Am J Med; 1980 Sep; 69(3):401-7. PubMed ID: 7416187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thyroglobulin levels to follow-up patients with treated differentiated thyroid carcinoma.
    Moser E; Braun S; Büell U; Kirsch CM; Tosch U; Wendt T
    Cancer Detect Prev; 1984; 7(2):79-86. PubMed ID: 6424939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma.
    Franceschi M; Kusić Z; Franceschi D; Lukinac L; Roncević S
    J Nucl Med; 1996 Mar; 37(3):446-51. PubMed ID: 8772642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma.
    Alnafisi NS; Driedger AA; Coates G; Moote DJ; Raphael SJ
    J Nucl Med; 2000 Jun; 41(6):1010-5. PubMed ID: 10855626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study.
    Franke WG; Zöphel K; Wunderlich GR; Mat R; Kühne A; Schimming C; Kropp J; Bredow J
    Cancer Detect Prev; 2000; 24(6):524-30. PubMed ID: 11198265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Technetium-99m tetrofosmin single photon emission computed tomography to detect metastatic papillary thyroid carcinoma in patients with elevated human serum thyroglobulin levels but negative I-131 whole body scan.
    Wu HS; Liu FY; Huang WS; Liu YC; Chang CT; Kao CH
    Clin Radiol; 2003 Oct; 58(10):787-90. PubMed ID: 14521888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of technetium-99m sestamibi whole-body scans in diagnosing metastatic Hürthle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 and thallium-201 whole-body scans.
    Yen TC; Lin HD; Lee CH; Chang SL; Yeh SH
    Eur J Nucl Med; 1994 Sep; 21(9):980-3. PubMed ID: 7995293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Total-body scintigraphy with thallium-201 and iodine-131 in the follow-up of differentiated thyroid cancer.
    Carril JM; Quirce R; Serrano J; Banzo I; Jiménez-Bonilla JF; Tabuenca O; Barquín RG
    J Nucl Med; 1997 May; 38(5):686-92. PubMed ID: 9170428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
    Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.